Paclitaxel-Triazine Dendrimer Constructs: Efficacy, Toxicity, and Characterization
This chapter reviews work from our laboratory over the last 10 years as it pertains to efforts focused on the exploration of triazine dendrimers as vehicles for drug delivery. The discussion is restricted to our efforts in paclitaxel-laden constructs, an area that we have had the most success and have made the greatest investment in time and energy. Areas of emphasis include the evolution of synthetic strategies, characterization, biodistribution, biocompatibility, safety and toxicity, efficacy, and therapeutic advantage. Throughout, limitations and challenges to these efforts are delineated. This chapter is not intended to exhaustively recapitulate the published work. Interested readers are referred to the original research publications and the supporting information provided with each. Instead, the intent is to provide insight into the evolution of the design and to realize this opportunity to share intuitions currently guiding these efforts which, accordingly, are less (or as yet un-) substantiated with experiment.
KeywordsHigh Pressure Liquid Chromatography Functional Monomer PAMAM Dendrimer Cyanuric Chloride Generation Dendrimers
The authors thank Dr. Sonke Svenson for the opportunity to convey the contents of our presentation at the National ACS Meeting in Boston (2010) in this forum. In addition to the long-standing efforts of coworkers identified in the relevant citations, the authors wish to thank Dr. Xiankai Sun and Su-Tang Lo of the University of Texas Southwestern Medical Center for ongoing collaboration in this area. Additionally, individuals of the Nanotechnology Characterization Laboratory who contributed to the collection of data on these dendrimers include Stephan Stern, Jeffrey D. Clogston, Jiwen Zheng, Pavan P. Adiseshaiah, Marina Dobrovolskaia, as led by Anil Patri. This work is supported with funds from Texas Christian University. The work is impacted by partnerships with others in related areas, including Drs. Thomas Kissel and Olivia Merkel in Marburg, Dr. Sunil Shaunak in London, Drs. Pete Choyke and Hisataka Kobayashi in Bethesda, and Giovanni Pavan at SUPSI.
- 9.Albain KS, Belani CP, Bonomi P, O’Byrne KJ, Schiller JH, Socinski M (2006) PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. Clin Lung Cancer 7:417–419CrossRefGoogle Scholar
- 10.Beeram M, Rowinsky EK, Hammond LA, Patnaik A, Schwartz GH, de Bono JS, Forero L, Forouzesh B, Berg KE, Rubin EH, Beers S, Killian A, Kwiatek J, McGuire J, Spivey L, Takimoto CH (2002) A phase I pharmacokinetic (PK) study of PEG-paclitaxel in patients with advanced solid tumors (Abstract). Proc Am Soc Clin Oncol 21:405Google Scholar
- 11.Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JH, Schot M, Mandjes IA, Zurlo MG, Rocchetti M, Rosing H, Koopman FJ, Beijnen JH (2001) Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 12:315–323CrossRefGoogle Scholar
- 19.Guillemard V, Saragovi HU (2001) Taxane-antibody conjugates afford potent cytotoxicity, enhanced solubility, and tumor target selectivity. Cancer Res 61:694–699Google Scholar
- 27.Venditto VJ, Allred K, Allred CD, Simanek EE (2009) Intercepting triazine dendrimer synthesis with nucleophilic pharmacophores as a general strategy toward drug delivery vehicles. Chem Commun 5541–5542Google Scholar
- 32.Chouai A, Venditto VJ, Simanek EE, Vanderplas BC, Ragan JA (2009) Large scale green synthesis of a generation-1 melamine (triazine) dendrimer. Organic Synth 86:151Google Scholar
- 35.Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 6:6387–6392Google Scholar
- 36.Majoros IJ, Myc C, Thomas T, Mehta CB, Baker JR, Jr. (2006) PAMAM dendrimer-based multifunctional conjugate for cancer therapy: Synthesis, characterization, and functionality. Biomacromolecules 7: 572Google Scholar